Eye

Global Vitamin A Market Analysis, Size, Trends and Forecasts to 2029 - A US$745.84 Million Market by 2029, with Expected CAGR of 5.26% Over 2024-2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Fitness & Nutrition, Health, Element, Meat, Urbanization, Growth, Vitamin A, Prevalence, Poultry, Application, Dietary supplement, Livestock, Eye, Skin, Nature, Aquaculture, Safety, Cosmetics, Vitamin A deficiency, Ageing

The global vitamin A market value stood at US$548.36 million in 2023 and is expected to reach US$745.84 million by 2029.

Key Points: 
  • The global vitamin A market value stood at US$548.36 million in 2023 and is expected to reach US$745.84 million by 2029.
  • The market is expected to grow at a CAGR of 5.26% over the projected period of 2024-2029.
  • The rising demand for functional foods, fortified with essential nutrients including vitamin A, has also contributed to market growth.
  • Overall, Asia Pacific's dynamic market landscape positions it as a key player in the global vitamin A sector.

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, MD, MBA, Patient, Eye, Safety, Pharmaceutical industry

Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
  • “We are very pleased to have begun dosing subjects in this trial in Canada,” said Michael Goldstein, MD, MBA, President and Chief Medical Officer of Aurion Biotech.
  • “Treating subjects in both the United States and Canada in our CLARA trial is an important milestone in our clinical development program.
  • The Phase 1 / 2 clinical trial (ABA-1, CLARA) is a prospective, multi-center, randomized, double masked, parallel-arm cell dose-ranging clinical trial in subjects with corneal edema secondary to corneal endothelial dysfunction.

Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Format

Retrieved on: 
Thursday, March 28, 2024
Men, Retail, Health, Consumer, Convenience Store, Lifestyle, General Health, Supermarket, Specialty, Fitness & Nutrition, Women, Seniors, Food, Beverage, Organic Food, D3, Beauty, Eye, UV, Vitamin C, Stevia, Skin, Dietary supplement

Nutrex-Hawaii, Inc., a wholly owned subsidiary of Cyanotech Corporation, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving.

Key Points: 
  • Nutrex-Hawaii, Inc., a wholly owned subsidiary of Cyanotech Corporation, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving.
  • "Today's consumers seek brands that align with their values of efficacy, transparency, and sustainability.
  • "With antioxidant potency 6000 times greater than Vitamin C, our BioAstin® Hawaiian Astaxanthin® gummies provide consumers with powerful benefits for full body wellness.
  • For more information about Nutrex-Hawaii and BioAstin® Hawaiian Astaxanthin® gummies, please visit https://www.nutrex-hawaii.com .

Tigo Energy Headquarters Receives 90kW of Optimized Solar from Long-Time Installer Partner

Retrieved on: 
Thursday, March 28, 2024
Environment, Commercial Building & Real Estate, Technology, Construction & Property, Other Energy, Software, Building Systems, Alternative Energy, Green Technology, Energy, Cloud, Tigo Energy, CCA, Pressure, Growth, Total quality management, Millicom, Solar Energy Industries Association, TAP, Eye, Safety, TQS, Multimedia, Renewable energy

Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the installation and commissioning of a rooftop solar system at its headquarters in California.

Key Points: 
  • Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the installation and commissioning of a rooftop solar system at its headquarters in California.
  • The system was designed and deployed by Tigo installer partner, Laibach Solar , and has averaged 5% Reclaimed Energy since it was commissioned.
  • View the full release here: https://www.businesswire.com/news/home/20240328503393/en/
    The system was designed and deployed by Tigo installer partner Laibach Solar and has averaged 5% Reclaimed Energy since it was commissioned.
  • Tigo is a great partner on our solar mission, and we look forward to many more years of empowering solar with great software and a shared commitment to quality.”
    With the Tigo Energy Intelligence monitoring platform , Laibach Solar and Tigo Energy have full control and visibility over the installation.

The Presidio Group Q4 Report: Dealer Profit Erosion, Falling Store Valuations

Retrieved on: 
Wednesday, March 27, 2024
General Automotive, Other Automotive, Automotive, Lexus, Pressure, Subaru, Acceleration, Coronavirus, Toyota, Eye, Presidio, OEM, Publication, Investment

The Q4 2023 edition of “Presidio Perspectives: A Quarterly Outlook on Auto Retail and M&A Trends” sums up the industry’s performance in 2023 and provides an outlook on trends happening in 2024.

Key Points: 
  • The Q4 2023 edition of “Presidio Perspectives: A Quarterly Outlook on Auto Retail and M&A Trends” sums up the industry’s performance in 2023 and provides an outlook on trends happening in 2024.
  • Presidio’s newest report details how macroeconomic, OEM and consumer trends are impacting the outlook for the retail automotive industry.
  • “This year will be choppier and will likely trend down overall,” said George Karolis, president of The Presidio Group.
  • The report also contains the results of the second quarterly Presidio Dealer Direction Survey.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Wednesday, March 27, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NMIBC, Research, Melanoma, Growth, Disease, SPA, Incidence, Paratriathlon, Inflammation, Patient, Necrosis, Travel, Light, Aes, American Academy, Cancer, Șaeș, Bladder cancer, Radiation, Eye, Doctor of Philosophy, MIBC, Visual acuity, Neoplasm, ILS, Aura, Safety, Recurrence, AAO, Annual general meeting, Food, Pharmaceutical industry

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
  • The primary endpoint is time to tumor progression when the last patient completes 15 months of follow up.
  • As of December 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $226.2 million.
  • General and administrative expenses include $1.2 million and $1.1 million of stock-based compensation for the three months ended December 31, 2023 and 2022, respectively.

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Neurology, Medical Devices, Health, Clinical Trials, PDQ, Depression, Parkinson's disease, Disease, Sleep, Patient, URMC, Research, Anxiety, University, Telehealth, Hope, Quality of life, Eye, Chet, Light, Clinical trial, Retina, Cognition, MDS, Tremor, Fatigue, FDA, The, Pharmaceutical industry

The "Celeste Light for PD Trial" (found at lightforpd.com) represents a significant stride in Parkinson’s disease (PD) treatment, leveraging innovative Spectramax™ technology through the passive and non-invasive Celeste® phototherapy device.

Key Points: 
  • The "Celeste Light for PD Trial" (found at lightforpd.com) represents a significant stride in Parkinson’s disease (PD) treatment, leveraging innovative Spectramax™ technology through the passive and non-invasive Celeste® phototherapy device.
  • This pivotal trial will assess the efficacy of Celeste®, the company’s FDA Breakthrough phototherapy device to improve non-motor and motor function and quality of life in Parkinson’s disease (PD).
  • This 300-patient phototherapy trial will be the largest trial of its kind.
  • “A pivotal trial for medical devices is similar to a phase 3 trial drug trial,” said Dan Adams, chief science officer.

Center For Sight Implants New FDA-Approved iDose®TR Device

Retrieved on: 
Tuesday, March 26, 2024
Surgery, Medical Devices, FDA, Hospitals, Biotechnology, Other Health, Health, General Health, Optical, Optic nerve, Ocular hypertension, Paratriathlon, Patient, Cataract, Eye, Multimedia, Intraocular pressure, Food, Medical device

The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.

Key Points: 
  • The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.
  • The device consistently distributes a travoprost formula to help reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
  • is a member of the US Eye Physician Advisory Board and is a Cataract and Glaucoma Surgeon at Center For Sight.
  • Speaking of the device, he shares, “We found the device and medication formula to work very well in our study patients.

Horus Pharma Renews Its Partnership With Plastic Bank

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Manufacturing, Other Health, Health, Environmental Issues, Environmental Health, Optical, Recycling, Other Manufacturing, Environment, Chemicals, Plastics, Partnership, Education, Eye, Multimedia, Plastic Bank, Social, Mediterranean Basin, Pharma, Ophthalmology

Horus Pharma, an independent French laboratory specialised in ophthalmology known for its expertise in developing preservative-free products designed to facilitate eye and eyelid health, has extended its successful collaboration with Plastic Bank, a global organisation focused on reducing and recycling plastic waste and championing a circular economy.

Key Points: 
  • Horus Pharma, an independent French laboratory specialised in ophthalmology known for its expertise in developing preservative-free products designed to facilitate eye and eyelid health, has extended its successful collaboration with Plastic Bank, a global organisation focused on reducing and recycling plastic waste and championing a circular economy.
  • View the full release here: https://www.businesswire.com/news/home/20240325128322/en/
    In late 2022, Horus Pharma made a pledge alongside Plastic Bank to recycle the quantity of plastic used in the packaging for 10 of its products.
  • Horus Pharma is thus offsetting 65% of the plastic volumes it puts on the market, with 400 metric tons of plastic set to be recycled between year-end 2022 and year-end 2025.
  • Nicolas Claret, Horus Pharma’s International Director, commented: “In the pharma industry, plastic often has to be used to meet regulatory standards and comply with globally recognised good manufacturing practices.